YY003

Phase 2Biologic

CChongqing Claruvis Pharmaceutical Co., Ltd.

YY003 is one of 3 biologic programs targeting Moderate to Severe Glabellar Lines. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moderate to Severe Glabellar LinesCompleted

Moderate to Severe Glabellar LinesPhase 2

Completed

Competition

Competitive Landscape

4 competitors in Moderate to Severe Glabellar Lines

#DrugCompanyPhaseTrials

Vehicle Control

LLubris Bio Pty Ltd

Phase 2

1 2

YY003

CChongqing Claruvis Pharmaceutical Co., Ltd.

Phase 2

1 3

AGN-151586

AbbVie

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Moderate to Severe Glabellar Lines1 trial

A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for the Treatment of Moderate to Severe Glabellar Lines in Adults

Completed·CChongqing Claruvis Pharmaceutical Co., Ltd.·Phase 2·NCT06481475·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for YY003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YY003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YY003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Claruvis Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CChongqing Claruvis Pharmaceutical Co., Ltd.

YY003

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Moderate to Severe Glabellar Lines1 trial

References

Drug Info

Quick Facts

Related News